Contents
Vol 12, Issue 559
Research Articles
- Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
An effective combination immunotherapy using oncolytic viruses delivers de novo CD19 to promote CD19-CAR T cell therapy against solid tumors in mice.
- C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy
G4C2 repeat–derived poly(GR) plays a key role in mediating TDP-43 mislocalization and aggregation in vitro and in vivo.
- Agrin induces long-term osteochondral regeneration by supporting repair morphogenesis
Agrin heals joint surfaces by recruiting joint stem cells and inducing the formation of cartilage and bone with correct architecture in mice and sheep.
- A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
YAP and FOXM1 are mediators of EGFR inhibitor resistance, and spindle proteins are therapeutic targets for this multidrug-resistant phenotype.
- SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control
SMOC1 is a liver-secreted glucose-responsive protein that improves glycemic control through CREB-mediated suppression of hepatic glucose output.
- A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Different serological assays measuring anti–SARS-CoV-2 antibodies and their neutralizing activity in samples from individuals with severe and mild COVID-19 are compared.
Editors' Choice
- Organoids control glucose
Human islet-like organoids improve glucose control in immunocompetent mice.
- PARP inhibitors unleash the antitumor immune response
Combination of a PARP inhibitor with immune checkpoint blockade showed promising antitumor activity without additional toxicity.
- Shedding light on heart failure
Optogenetic stimulation of vagal preganglionic neurons preserved left ventricular ejection fraction in an experimental heart failure model.
About The Cover

ONLINE COVER CAR and Driver. Chimeric antigen receptor (CAR) T cells are a cancer immunotherapy engineered to recognize a specific antigen on a tumor surface. CAR T cell therapy can result in damage to healthy cells and/or tumor cells escaping destruction when a convenient target tumor antigen is not available. To address this problem, Park et al. first infected tumors with an oncolytic virus to express the antigen CD19, then delivered CAR T cells recognizing CD19 to destroy these tumors. The image shows a tumor infected with an oncolytic virus (green), with cell nuclei in blue. [CREDIT: A. K. PARK, S.-I. KIM, S. J. PRICEMAN/CITY OF HOPE]